Skip to main content

A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis

Abstract

Background

Pulmonary metastasectomy has been widely adopted in the treatment of metastatic disease. In recent years image guided ablation has seen increased use in the treatment of thoracic malignancies. The objective of this study was to evaluate oncological outcomes following percutaneous ablation (PA) of pulmonary metastasis.

Methods

A comprehensive search of the PubMed, MEDLINE and EMBASE databases from January 2000 to August 2021 was performed to identify studies evaluating patient survival following ablation of lung metastasis. Pooled outcomes have been presented with a random effects model to assess primary outcomes of overall survival, progression free survival and 1-year local control. Secondary outcomes included procedural mortality, major complications, and the incidence of pneumothorax.

Results

A total of 24 studies were identified. The pooled median overall survival was 5.13 [95% confidence interval (CI): 4.37–6.84] years, and the 1-, 3-, 5-year progression free survival rates were 53%, 26% and 20% respectively. The 1-year local control rate was 91% (95%CI: 86–95%). Periprocedural mortality was rare (0%; 95%CI: 0–1%), as were major complications excluding pneumothorax (1%; 95%CI: 1–2%). Pneumothorax developed in 44% of ablation sessions, although only half of these required chest tube placement. Most patients were able to be discharged day one post-procedurally.

Conclusion

PA demonstrates high overall, progression free and local tumour survival in patients with lung metastasis. Complications and mortality are also rare. Consideration of its use should be made in a tumour board meeting in conjunction with surgical and radiotherapy perspectives for targeted local control of metastases.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Hess KR, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.

    PubMed  Article  Google Scholar 

  2. Pastorino U, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.

    CAS  PubMed  Article  Google Scholar 

  3. de Baere T, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240(2):587–96.

    PubMed  Article  Google Scholar 

  4. Dupuy DE, et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174(1):57–9.

    CAS  PubMed  Article  Google Scholar 

  5. Paez-Carpio A, et al. Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art. Insights Imaging. 2021;12(1):57.

    PubMed  PubMed Central  Article  Google Scholar 

  6. Nguyen CL, et al. Radiofrequency ablation of primary lung cancer: results from an ablate and resect pilot study. Chest. 2005;128(5):3507–11.

    PubMed  Article  Google Scholar 

  7. Lencioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9(7):621–8.

    PubMed  Article  Google Scholar 

  8. Jiang B, et al. Efficacy and safety of thermal ablation of lung malignancies: a Network meta-analysis. Ann Thorac Med. 2018;13(4):243–50.

    PubMed  PubMed Central  Article  Google Scholar 

  9. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.

    PubMed  Article  Google Scholar 

  10. Trotti A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.

    PubMed  Article  Google Scholar 

  11. Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33(15):2521–37.

    PubMed  Article  Google Scholar 

  12. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–60.

    PubMed  Article  Google Scholar 

  13. Higgins JP, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    PubMed  PubMed Central  Article  Google Scholar 

  14. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.

    PubMed  PubMed Central  Article  Google Scholar 

  15. Bin Traiki TA, et al. Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(10):1939–48.

    CAS  PubMed  Article  Google Scholar 

  16. Bonichon F, et al. Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network. Endocrine. 2021;72(3):798–808.

    CAS  PubMed  Article  Google Scholar 

  17. Callstrom MR, et al. Multicenter study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE). J Thorac Oncol. 2020;15(7):1200–9.

    PubMed  PubMed Central  Article  Google Scholar 

  18. de Baère T, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987–91.

    PubMed  PubMed Central  Article  Google Scholar 

  19. de Baere T, et al. The ECLIPSE study: efficacy of cryoablation on metastatic lung tumors with a 5-year follow-up. J Thorac Oncol. 2021;16(11):1840–9.

    PubMed  Article  CAS  Google Scholar 

  20. Gonnet A, et al. Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience. BMC Cancer. 2019;19(1):1182.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. Hasegawa T, et al. Three-year survival rate after radiofrequency ablation for surgically resectable colorectal lung metastases: a prospective multicenter study. Radiology. 2020;294(3):686–95.

    PubMed  Article  Google Scholar 

  22. Hiraki T, et al. Percutaneous radiofrequency ablation for pulmonary metastases from hepatocellular carcinoma: results of a multicenter study in Japan. J Vasc Interv Radiol. 2011;22(6):741–8.

    PubMed  Article  Google Scholar 

  23. Kawamura M, et al. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. J Thorac Cardiovasc Surg. 2006;131(5):1007–13.

    PubMed  Article  Google Scholar 

  24. Koelblinger C, Strauss S, Gillams A. Outcome after radiofrequency ablation of sarcoma lung metastases. Cardiovasc Intervent Radiol. 2014;37(1):147–53.

    PubMed  Article  Google Scholar 

  25. Leppelmann KS, et al. Outcomes following percutaneous microwave and cryoablation of lung metastases from adenoid cystic carcinoma of the head and neck: a bi-institutional retrospective cohort study. Ann Surg Oncol. 2021;28(11):5829–39.

    PubMed  Article  Google Scholar 

  26. Matsui Y, et al. Long-term survival following percutaneous radiofrequency ablation of colorectal lung metastases. J Vasc Interv Radiol. 2015;26(3):303–10.

    PubMed  Article  Google Scholar 

  27. Nakamura T, et al. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas [corrected]. Cancer. 2009;115(16):3774–81.

    PubMed  Article  Google Scholar 

  28. Omae K, et al. Long-term survival after radiofrequency ablation of lung oligometastases from five types of primary lesions: a retrospective evaluation. J Vasc Interv Radiol. 2016;27(9):1362–70.

    PubMed  Article  Google Scholar 

  29. Pennathur A, et al. Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg. 2009;88(5):1601–6.

    PubMed  PubMed Central  Article  Google Scholar 

  30. Sato T, et al. Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients. Jpn J Radiol. 2017;35(2):61–7.

    PubMed  Article  Google Scholar 

  31. Simon CJ, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243(1):268–75.

    PubMed  Article  Google Scholar 

  32. Soga N, et al. Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. BJU Int. 2009;104(6):790–4.

    PubMed  Article  Google Scholar 

  33. Tselikas L, et al. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. Diagn Interv Imaging. 2021;102(1):19–26.

    CAS  PubMed  Article  Google Scholar 

  34. von Meyenfeldt EM, et al. Local progression after radiofrequency ablation for pulmonary metastases. Cancer. 2011;117(16):3781–7.

    Article  Google Scholar 

  35. Yamakado K, et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol. 2007;18(3):393–8.

    PubMed  Article  Google Scholar 

  36. Yamakado K, et al. Long-term results of radiofrequency ablation in colorectal lung metastases: single center experience. Oncol Rep. 2009;22(4):885–91.

    PubMed  Article  Google Scholar 

  37. Yan TD, et al. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14(5):1718–26.

    PubMed  Article  Google Scholar 

  38. Zhong J, et al. Long-term outcomes in percutaneous radiofrequency ablation for histologically proven colorectal lung metastasis. Cardiovasc Intervent Radiol. 2020;43(12):1900–7.

    PubMed  PubMed Central  Article  Google Scholar 

  39. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.

    CAS  PubMed  Article  Google Scholar 

  40. Leung KM, Elashoff RM, Afifi AA. Censoring issues in survival analysis. Annu Rev Public Health. 1997;18:83–104.

    CAS  PubMed  Article  Google Scholar 

  41. Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017;15(1):133.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  42. Sun YD, et al. Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: a systematic review and meta-analysis. Thorac Cancer. 2019;10(3):543–50.

    PubMed  PubMed Central  Article  Google Scholar 

  43. Dziedzic R, et al. Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg. 2017;52(2):363–9.

    PubMed  Article  Google Scholar 

  44. Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S.

    CAS  PubMed  Article  Google Scholar 

  45. Gossling GCL, et al. Outcomes and prognostic factors of patients with metastatic colorectal cancer who underwent pulmonary metastasectomy with curative intent: a Brazilian experience. Oncologist. 2021;26(9):e1581–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. Hornbech K, Ravn J, Steinbruchel DA. Outcome after pulmonary metastasectomy: analysis of 5 years consecutive surgical resections 2002–2006. J Thorac Oncol. 2011;6(10):1733–40.

    PubMed  Article  Google Scholar 

  47. Cao C, et al. A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. J Thorac Dis. 2019;11(12):5187–98.

    PubMed  PubMed Central  Article  Google Scholar 

  48. Cumpston M, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.

    PubMed  Google Scholar 

  49. Hess LM, et al. Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. J Cancer. 2019;10(16):3717–27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. Lodeweges JE, et al. Long-term outcome of surgery or stereotactic radiotherapy for lung oligometastases. J Thorac Oncol. 2017;12(9):1442–5.

    PubMed  Article  Google Scholar 

  51. Cheung FP, Alam NZ, Wright GM. The past, present and future of pulmonary metastasectomy: a review article. Ann Thorac Cardiovasc Surg. 2019;25(3):129–41.

    PubMed  PubMed Central  Article  Google Scholar 

  52. Liu J, et al. The application of computed tomography-guided percutaneous coaxial biopsy combined with microwave ablation for pulmonary tumors. J Cancer Res Ther. 2019;15(4):760–5.

    PubMed  Article  Google Scholar 

  53. Tselikas L, et al. Diagnostic yield of a biopsy performed immediately after lung radiofrequency ablation. Eur Radiol. 2017;27(3):1211–7.

    PubMed  Article  Google Scholar 

  54. Milosevic M, et al. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients—control survival is much better than previously assumed. Colorectal Dis. 2020;22(10):1314–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. Palma DA, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8.

    PubMed  Article  Google Scholar 

  56. Ruers T, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djx015.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: “when is enough, enough?” JAMA. 2008;299(22):2667–78.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Funding

This study was not supported by any funding.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Minhtuan Nguyenhuy.

Ethics declarations

Conflict of interest

The author(s) declare(s) that there is no conflict of interest.

Ethical Approval

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nguyenhuy, M., Xu, Y., Maingard, J. et al. A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis. Cardiovasc Intervent Radiol 45, 1102–1113 (2022). https://doi.org/10.1007/s00270-022-03116-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-022-03116-z

Keywords

  • Embolization
  • Lung
  • Pulmonary
  • Ablation
  • Oncology